Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin of 29.8% Continued growth inves...
Pfizer does not endorse TRC Capital Investment’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in respons...
QIAGEN announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase tha...
Inaugural strategy is one of the largest ever first-time private life sciences growth funds Fundraise closed above its original target, reflecting stron...
"Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this sp...
The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.&nb...
ImpriMed, a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, announced the close of a $2...
Parse Biosciences, a leading provider of easily accessible and scalable solutions for single-cell sequencing, announced today that the company has raised $...
Series A led by Sofinnova Partners and OMX Ventures Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, announced today a ...
Ten projects will receive funding to help address adult immunization gaps in communities across the country GSK launched the COiMMUNITY Initiative in Ju...
Perpetual Medicines announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for pe...
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, O...
The oversubscribed capital raise was led by existing venture capital investors: U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and...
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment Fundraise led by Sofin...
© 2026 Biopharma Boardroom. All Rights Reserved.